Macquarie Group Ltd. raised its position in Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 0.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 121,700 shares of the company’s stock after buying an additional 350 shares during the period. Macquarie Group Ltd.’s holdings in Zimmer Biomet Holdings were worth $14,650,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Tower Research Capital LLC TRC boosted its position in shares of Zimmer Biomet Holdings by 205.3% in the second quarter. Tower Research Capital LLC TRC now owns 916 shares of the company’s stock worth $110,000 after buying an additional 616 shares during the period. Global X Management Co. LLC boosted its position in shares of Zimmer Biomet Holdings by 238.4% in the second quarter. Global X Management Co. LLC now owns 1,032 shares of the company’s stock worth $124,000 after buying an additional 727 shares during the period. Enterprise Financial Services Corp boosted its position in shares of Zimmer Biomet Holdings by 173.9% in the second quarter. Enterprise Financial Services Corp now owns 1,260 shares of the company’s stock worth $151,000 after buying an additional 800 shares during the period. IFP Advisors Inc boosted its position in shares of Zimmer Biomet Holdings by 0.5% in the second quarter. IFP Advisors Inc now owns 1,507 shares of the company’s stock worth $181,000 after buying an additional 8 shares during the period. Finally, Taurus Asset Management LLC acquired a new position in shares of Zimmer Biomet Holdings during the second quarter worth $205,000. 85.05% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.63% during midday trading on Tuesday, hitting $103.64. 1,069,328 shares of the stock were exchanged. The stock’s 50 day moving average is $112.33 and its 200 day moving average is $121.63. The firm has a market cap of $20.76 billion, a P/E ratio of 58.03 and a beta of 1.28. Zimmer Biomet Holdings Inc. has a 12-month low of $88.27 and a 12-month high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.79. The firm had revenue of $1.83 billion for the quarter, compared to analyst estimates of $950.20 million. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.64 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings Inc. will post $7.92 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Macquarie Group Ltd. Buys 350 Shares of Zimmer Biomet Holdings Inc. (ZBH)” was posted by Financial Market News and is owned by of Financial Market News. If you are reading this article on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this article can be read at http://www.financial-market-news.com/macquarie-group-ltd-buys-350-shares-of-zimmer-biomet-holdings-inc-zbh/1208591/.

A number of brokerages have recently weighed in on ZBH. Citigroup Inc. raised shares of Zimmer Biomet Holdings from a “sell” rating to a “neutral” rating in a research note on Tuesday. Leerink Swann reaffirmed an “outperform” rating and issued a $136.00 target price (down from $150.00) on shares of Zimmer Biomet Holdings in a research note on Tuesday, November 1st. SunTrust Banks Inc. assumed coverage on shares of Zimmer Biomet Holdings in a research note on Thursday, August 11th. They issued a “buy” rating and a $155.00 target price for the company. RBC Capital Markets reaffirmed an “outperform” rating and issued a $130.00 target price (down from $143.00) on shares of Zimmer Biomet Holdings in a research note on Tuesday, November 1st. Finally, Jefferies Group lowered their target price on shares of Zimmer Biomet Holdings from $150.00 to $129.00 and set a “buy” rating for the company in a research note on Tuesday, November 1st. Four research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has an average rating of “Buy” and an average price target of $131.15.

In other news, insider Daniel E. Williamson sold 2,716 shares of the stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $129.96, for a total transaction of $352,971.36. Following the transaction, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.